filanesib multiple myeloma - Google News

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma - DocWire News

over 3 years ago

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple...

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma - DocWire News

over 3 years ago

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple...

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma - DocWire News

over 3 years ago

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple...

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma - DocWire News

over 3 years ago

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple...

Kinesin Spindle Protein Market Size, Key Opportunities, Strategic Assessment, Strong Revenue – The Canton Independent Sentinel - The Canton Independent Sentinel

over 3 years ago

Kinesin Spindle Protein Market Size, Key Opportunities, Strategic Assessment, Strong Revenue –...

Use of carfilzomib in second-line therapy and beyond for relapsed mult | BLCTT - Dove Medical Press

almost 8 years ago

Use of carfilzomib in second-line therapy and beyond for relapsed mult |...

Oncothyreon And Array BioPharma Announce Phase 1b Trial For ONT-380 In Breast Cancer - Clinical Leader

over 8 years ago

Oncothyreon And Array BioPharma Announce Phase 1b Trial For ONT-380 In Breast...

APAC multiple myeloma drug market value to reach $2.8b - European Pharmaceutical Review

over 9 years ago

Array appoints Victor Sandor chief medical officer - PMLiVE

almost 11 years ago

ARRAY BIOPHARMA ANNOUNCES CLINICAL DATA PRESENTATIONS AT THE 2014 ASCO ANNUAL MEETING - Bio-IT World

about 11 years ago